Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.19 EUR | +3.26% | +0.21% | -32.86% |
03-26 | Visiomed: share price rises on 'record' 2023 results | CF |
02-13 | Visiomed: 38% increase in annual sales | CF |
Valuation
Fiscal Period: December | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 |
---|---|---|---|---|---|---|
Capitalization 1 | 28.94 | 6.061 | 12.87 | 22.43 | 11.49 | 98.55 |
Enterprise Value (EV) 1 | 25.54 | 8.198 | 9.018 | 21.66 | 9.877 | 101.8 |
P/E ratio | -1.46 x | -0.18 x | -0.39 x | -3.19 x | -1.33 x | -22.7 x |
Yield | - | - | - | - | - | - |
Capitalization / Revenue | 2.77 x | 0.69 x | 1.26 x | 1.18 x | 1.6 x | 6.82 x |
EV / Revenue | 2.44 x | 0.94 x | 0.88 x | 1.14 x | 1.38 x | 7.05 x |
EV / EBITDA | -1.95 x | -0.47 x | -0.5 x | -3.49 x | -3.43 x | -68.6 x |
EV / FCF | -2.06 x | -1.43 x | -1.24 x | -2.45 x | 3.8 x | -6.37 x |
FCF Yield | -48.4% | -69.7% | -81% | -40.8% | 26.3% | -15.7% |
Price to Book | 2.28 x | 16.7 x | -2.52 x | -5.08 x | 0.92 x | 4.94 x |
Nbr of stocks (in thousands) | 709 | 1,774 | 14,359 | 25,400 | 121,996 | 241,834 |
Reference price 2 | 40.80 | 3.416 | 0.8960 | 0.8830 | 0.0942 | 0.4075 |
Announcement Date | 30/04/18 | 30/04/19 | 31/03/20 | 31/03/21 | 01/04/22 | 26/04/23 |
Income Statement Evolution (Annual data)
Fiscal Period: December | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 |
---|---|---|---|---|---|---|
Net sales 1 | 10.47 | 8.746 | 10.24 | 19.02 | 7.179 | 14.44 |
EBITDA 1 | -13.09 | -17.45 | -18.1 | -6.199 | -2.876 | -1.484 |
EBIT 1 | -13.72 | -18.16 | -18.88 | -6.581 | -3.677 | -4.082 |
Operating Margin | -131.14% | -207.63% | -184.38% | -34.59% | -51.22% | -28.26% |
Earnings before Tax (EBT) 1 | -13.66 | -20.13 | -24.24 | -5.314 | -4.315 | -5.164 |
Net income 1 | -13.15 | -19.79 | -24.38 | -5.15 | -4.457 | -5.277 |
Net margin | -125.69% | -226.24% | -238.11% | -27.07% | -62.08% | -36.53% |
EPS 2 | -28.00 | -18.83 | -2.318 | -0.2766 | -0.0706 | -0.0179 |
Free Cash Flow 1 | -12.37 | -5.713 | -7.302 | -8.843 | 2.598 | -15.99 |
FCF margin | -118.23% | -65.32% | -71.32% | -46.48% | 36.19% | -110.71% |
FCF Conversion (EBITDA) | - | - | - | - | - | - |
FCF Conversion (Net income) | - | - | - | - | - | - |
Dividend per Share | - | - | - | - | - | - |
Announcement Date | 30/04/18 | 30/04/19 | 31/03/20 | 31/03/21 | 01/04/22 | 26/04/23 |
Balance Sheet Analysis
Fiscal Period: December | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 |
---|---|---|---|---|---|---|
Net Debt 1 | - | 2.14 | - | - | - | 3.26 |
Net Cash position 1 | 3.4 | - | 3.85 | 0.77 | 1.62 | - |
Leverage (Debt/EBITDA) | - | -0.1225 x | - | - | - | -2.194 x |
Free Cash Flow 1 | -12.4 | -5.71 | -7.3 | -8.84 | 2.6 | -16 |
ROE (net income / shareholders' equity) | -126% | -304% | 1,026% | 108% | -92.2% | -27.5% |
ROA (Net income/ Total Assets) | -43.4% | -58.7% | -70.9% | -39.9% | -9.2% | -6.37% |
Assets 1 | 30.32 | 33.7 | 34.36 | 12.92 | 48.46 | 82.9 |
Book Value Per Share 2 | 17.90 | 0.2000 | -0.3600 | -0.1700 | 0.1000 | 0.0800 |
Cash Flow per Share 2 | 4.180 | 0.1200 | 0.4500 | 0.0300 | 0.0500 | 0.0100 |
Capex 1 | 0.67 | 0.76 | 0.06 | 0.25 | 0.2 | 5.52 |
Capex / Sales | 6.42% | 8.71% | 0.55% | 1.29% | 2.73% | 38.18% |
Announcement Date | 30/04/18 | 30/04/19 | 31/03/20 | 31/03/21 | 01/04/22 | 26/04/23 |
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
1st Jan change | Capi. | |
---|---|---|
-32.86% | 59.69M | |
-2.31% | 187B | |
-3.20% | 106B | |
-5.04% | 66.9B | |
+0.20% | 49.45B | |
+17.29% | 48B | |
+4.06% | 40.84B | |
+2.07% | 26.48B | |
+2.36% | 26.25B | |
+12.96% | 24.62B |
- Stock Market
- Equities
- ALVMG Stock
- Financials Visiomed Group SA